Pictet Asset Management Holding SA Boosts Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Pictet Asset Management Holding SA increased its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 23.4% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 442,484 shares of the company's stock after acquiring an additional 83,964 shares during the quarter. Pictet Asset Management Holding SA owned 0.54% of IDEXX Laboratories worth $182,941,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the stock. Insight Wealth Strategies LLC grew its stake in IDEXX Laboratories by 230.5% in the fourth quarter. Insight Wealth Strategies LLC now owns 10,096 shares of the company's stock valued at $4,174,000 after acquiring an additional 7,041 shares during the period. Geode Capital Management LLC grew its position in IDEXX Laboratories by 1.8% in the 3rd quarter. Geode Capital Management LLC now owns 2,259,537 shares of the company's stock valued at $1,138,732,000 after purchasing an additional 40,349 shares during the period. Y Intercept Hong Kong Ltd bought a new stake in IDEXX Laboratories during the 3rd quarter valued at $1,263,000. Sax Wealth Advisors LLC increased its stake in IDEXX Laboratories by 76.3% during the 4th quarter. Sax Wealth Advisors LLC now owns 1,426 shares of the company's stock valued at $590,000 after purchasing an additional 617 shares in the last quarter. Finally, Hantz Financial Services Inc. raised its holdings in IDEXX Laboratories by 11.5% during the fourth quarter. Hantz Financial Services Inc. now owns 7,738 shares of the company's stock worth $3,199,000 after buying an additional 800 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

IDXX has been the subject of several recent research reports. Morgan Stanley decreased their target price on shares of IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating for the company in a research report on Wednesday, January 29th. Barclays lifted their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a research note on Tuesday, February 4th. Bank of America increased their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a research note on Tuesday, February 4th. StockNews.com cut IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Tuesday, March 25th. Finally, Piper Sandler increased their price target on IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a research report on Monday, February 10th. Four analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $533.75.

IDEXX Laboratories Stock Performance

Shares of NASDAQ IDXX traded up $5.91 during mid-day trading on Wednesday, reaching $424.48. 178,044 shares of the company's stock were exchanged, compared to its average volume of 582,582. The firm has a 50-day moving average price of $436.90 and a two-hundred day moving average price of $441.45. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. The firm has a market capitalization of $34.41 billion, a price-to-earnings ratio of 39.78, a price-to-earnings-growth ratio of 3.41 and a beta of 1.39. IDEXX Laboratories, Inc. has a 52 week low of $398.50 and a 52 week high of $548.88.

Insider Buying and Selling

In related news, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the sale, the director now owns 3,061 shares of the company's stock, valued at approximately $1,426,242.34. This trade represents a 49.50 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP George Fennell sold 9,986 shares of the company's stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the sale, the executive vice president now directly owns 8,176 shares in the company, valued at approximately $3,781,645.28. This trade represents a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.11% of the stock is currently owned by corporate insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.